Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) has scheduled a conference call and webcast for June 17, 2025, at 8:00am ET to discuss interim results from Phase 1 healthy volunteer trials of their SPY002 program. The program focuses on novel half-life extended anti-TL1A antibodies for treating Inflammatory Bowel Disease (IBD) and other immune-mediated diseases. The presentation will be accessible through the company's Investor Relations webpage, with an archived version available for a limited time at https://ir.spyre.com/events-and-presentations.

News Market Reaction

-11.64%

1 alert

-11.64% News Effect

On the day this news was published, SYRE declined 11.64%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025. Following the announcement, the Company will host a conference call and webcast at 8:00am ET to discuss the results.

To access the live and archived webcast, please visit the Investor Relations page of Spyre's website at https://ir.spyre.com/events-and-presentations. The archived webcast will be available for a limited time on the Company's website.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create next-generation inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-to-host-conference-call-and-webcast-to-report-interim-results-from-phase-1-healthy-volunteer-trials-for-its-spy002-program-its-novel-half-life-extended-anti-tl1a-antibodies-on-june-17-2025-302482779.html

SOURCE Spyre Therapeutics, Inc.

FAQ

When will Spyre Therapeutics (SYRE) report Phase 1 interim results for SPY002?

Spyre Therapeutics will report Phase 1 interim results for SPY002 on Tuesday, June 17, 2025, followed by a conference call and webcast at 8:00am ET.

What is the therapeutic focus of Spyre Therapeutics' SPY002 program?

SPY002 consists of novel half-life extended anti-TL1A antibodies designed to treat Inflammatory Bowel Disease (IBD) and other immune-mediated diseases.

How can investors access Spyre Therapeutics' (SYRE) Phase 1 results webcast?

Investors can access the webcast through Spyre's Investor Relations webpage at https://ir.spyre.com/events-and-presentations.

What stage of development is Spyre Therapeutics' (SYRE) SPY002 program currently in?

SPY002 is currently in Phase 1 clinical trials with healthy volunteers, with interim results to be reported.